We're thrilled to share that Enlaza Therapeutics has been named to C&EN's prestigious list of Top 10 Startups to Watch! This recognition highlights our work in pioneering a groundbreaking therapeutic class—covalent biologics—that holds the potential for enhanced efficacy and safety. Our platform offers vast possibilities across all therapeutic areas. Huge thanks to our team for their dedication in driving this vision forward! See the list here: https://lnkd.in/gunzUhhJ #10StartUpsToWatch #covalentbiologics #WarLock #financing #biotech #SanDiego #oncology #cancer #cancers #antibodydrugconjugates #ADC
关于我们
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock? platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
- 网站
-
www.enlazatx.com
Enlaza Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 私人持股
- 领域
- Biotech、Antibody Drug Conjugates、Covalent Biologics、Covalent Protein Drugs和Oncology
地点
-
主要
获取路线
US，CA，San Diego
Enlaza Therapeutics员工
动态
-
We are excited to welcome Jeffrey Leiden, M.D., Ph.D., Executive Chairperson and former CEO of Vertex Pharmaceuticals, to Enlaza as a Key Advisor. Dr. Leiden will help guide the development of a high-value pipeline of first-in-class covalent protein drugs from Enlaza’s War-Lock? platform. Read the release here: https://lnkd.in/ggpmjniK #covalentbiologics #WarLock #biotech #leadership #oncology #cancer #cancers #antibodydrugconjugates #ADC
-
We are excited to announce a $100 million Series A financing to advance the first covalent biologics into the clinic! With this financing, we will further develop Enlaza’s proprietary War-Lock? covalent biologic platform and support advancement of wholly owned pipeline programs to the clinic. We look forward to creating a new class of therapeutics with targeted efficacy and low toxicity to improve the treatment of #cancer and other serious diseases. Sending thanks to our amazing syndicate: ?? J.P. Morgan Private Capital for leading the Series A ?? Frazier Healthcare Partners, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital for your continued support ?? Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments for joining us in our mission Read the release here: https://lnkd.in/gxFKWRUM? #covalentbiologics #WarLock #financing #biotech #SanDiego #oncology #cancers #antibodydrugconjugates #ADC?
Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital - Enlaza Therapeutics
https://enlazatx.com